7Baggers

Akebia Therapeutics Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Gross Profit  
 Operating Profit  
 Net Income  
20190331 20190630 20190930 20191231 20200331 20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 -175.75-132.54-89.32-46.1-2.8940.3383.54126.76Milllion

Akebia Therapeutics Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 
  revenue56,196,000 42,046,000 56,376,000 40,127,000 55,180,000 48,964,000 126,759,000 61,699,000 59,605,000 48,756,000 52,913,000 52,304,000 56,699,000 59,988,000 90,142,000 88,478,000 69,555,000 91,977,000 100,803,000 72,666,000 59,850,000 53,169,000 48,793,000 45,930,000 87,316,000 41,283,000 28,520,000 20,865,000 1,535,000 
  cost of revenue19,060,000 18,009,000 17,284,000 19,484,000 2,055,000 37,947,000 18,600,000 31,344,000 50,350,000 15,944,000 52,495,000 34,606,000 63,234,000 30,345,000 174,616,000 27,713,000 38,147,000 38,263,000 37,669,000 31,257,000 7,685,000 
  gross profit37,136,000 24,037,000 39,092,000 20,643,000 53,125,000 11,017,000 108,159,000 30,355,000 9,255,000 32,812,000 418,000 17,698,000 -6,535,000 29,643,000 -84,474,000 60,765,000 31,408,000 53,714,000 63,134,000 41,409,000 52,165,000 53,169,000 48,793,000 45,930,000 87,316,000 41,283,000 28,520,000 20,865,000 1,535,000 
  operating expenses                             
  research and development9,472,000 13,330,000 20,197,000 19,686,000 31,904,000 27,350,000 26,027,000 43,833,000 29,556,000 40,471,000 37,214,000 40,611,000 37,578,000 46,857,000 52,819,000 81,231,000 80,412,000 74,512,000 85,694,000 82,351,000 87,113,000 70,634,000 71,917,000 61,404,000 68,382,000 58,711,000 43,751,000 60,049,000 33,435,000 
  sales, general and administrative                             
  total operating expenses35,762,000 36,904,000 48,182,000 45,475,000 63,403,000 59,011,000 59,726,000 88,848,000 75,410,000 87,698,000 79,759,000 82,634,000 78,868,000 87,738,000 89,345,000 119,890,000 126,299,000 109,619,000 122,657,000 117,378,000 142,301,000 81,012,000 84,455,000 70,428,000 75,949,000 65,459,000 50,656,000 65,837,000 39,579,000 
  operating income1,374,000 -13,036,000 -8,996,000 -24,832,000 -5,129,000 -47,994,000 48,844,000 -58,493,000 -66,155,000 -54,886,000 -79,341,000 -64,936,000 -85,403,000 -58,095,000 -173,819,000 -59,125,000 -94,891,000 -55,905,000 -59,523,000 -75,969,000 -90,136,000 -27,843,000 -35,662,000 -24,498,000 11,367,000 -24,176,000 -22,136,000 -44,972,000 -38,044,000 
  net income614,000 -14,489,000 -11,172,000 -16,738,000 -8,755,000 -55,736,000 29,276,000 -66,349,000 -70,678,000 -59,544,000 -83,038,000 -69,580,000 -87,000,000 -59,959,000 -175,751,000 -60,747,000 -94,483,000 -54,585,000 -58,170,000 -72,421,000 -88,370,000 -26,047,000 -34,069,000 -23,418,000 12,280,000 -23,134,000 -21,518,000 -44,543,000 -37,862,000 

We provide you with 20 years income statements for Akebia Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Akebia Therapeutics stock. Explore the full financial landscape of Akebia Therapeutics stock with our expertly curated income statements.

The information provided in this report about Akebia Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.